title: Microencapsulated conjugated linoleic acid associated with hypocaloric diet reduces body fat in sedentary women with metabolic syndrome.
abstract: BACKGROUND
  Animal studies have suggested beneficial effects of conjugated linoleic acid (CLA) in reducing body fat mass and improvement in the serum lipid profile and glycemia. However, these effects are controversial in humans. The purpose of this study was to investigate the effects of microencapsulated CLA supplementation on body composition, body mass index, waist circumference, and blood pressure in sedentary women with metabolic syndrome.
  
  
  METHODS
  This study was a placebo-controlled and randomized clinical trial. Fourteen women diagnosed with metabolic syndrome received light strawberry jam enriched or not with microencapsulated CLA (3 g/day) as a mixture of 38.57% cis-9, trans-11, and 39.76% trans-10, cis-12 CLA isomers associated with a hypocaloric diet for 90 days. The subjects were monitored to assess variables associated with the metabolic syndrome, in addition to assessing adherence with the intervention.
  
  
  RESULTS
  There were no significant effects of microencapsulated CLA on the lipid profile or blood pressure. Mean plasma insulin concentrations were significantly lower in women supplemented with microencapsulated CLA (Δ T₉₀ - T₀ = -12.87 ± 4.26 μU/mL, P = 0.02). Microencapsulated CLA supplementation did not alter the waist circumference, but there was a reduction in body fat mass detected after 30 days (Δ = -2.68% ± 0.82%, P = 0.02), which was maintained until the 90-day intervention period (Δ = -3.32% ± 1.41%, P = 0.02) in the microencapsulated CLA group. The placebo group showed this effect only after 90 days (Δ = -1.97% ± 0.60%, P = 0.02), but had a reduced waist circumference (Δ T₉₀ - T₀ = -4.25 ± 1.31 cm, P = 0.03).
  
  
  CONCLUSIONS
  Supplementation with mixed-isomer microencapsulated CLA may have a favorable effect on glycemic control and body fat mass loss at an earlier time in sedentary women with metabolic syndrome, although there were no effects on lipid profile and blood pressure.
authors.affiliation: Medicine Department, Federal University of Rio de Janeiro, Brazil.
authors.forename: Roberta F
authors.initials: RF
authors.lastname: Carvalho
authors.forename: Sofia K
authors.initials: SK
authors.lastname: Uehara
authors.forename: Glorimar
authors.initials: G
authors.lastname: Rosa
mesh_terms: D050154:Adiposity; D000328:Adult; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D015992:Body Mass Index; D001938:Brazil; D031204:Caloric Restriction; D003131:Combined Modality Therapy; D005260:Female; D005527:Food, Fortified; D006801:Humans; D007328:Insulin / Q000097:blood; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000178:diet therapy* / Q000503:physiopathology; D057185:Sedentary Behavior; D013997:Time Factors; D016896:Treatment Outcome; D055105:Waist Circumference
chemical_list: D015415:Biomarkers; D007328:Insulin; D044243:Linoleic Acids, Conjugated; D008055:Lipids